At a Glance : Discover the transformative potential of Spravato (esketamine) therapy at Seaside Ketamine in Newport Beach! If you’re dealing with treatment-resistant depression, anxiety, or PTSD, our solutions provide rapid relief when standard treatments fail. Spravato, an FDA-approved nasal spray, is a valuable alternative with established insurance pathways for qualifying patients. Experience Ketamine-Assisted Psychotherapy and confront trauma with less fear. Don’t let anxiety or depression hold you back—schedule your free consultation today and take the first step towards a brighter future! Your journey to renewed hope starts here.
For Newport Beach patients with treatment-resistant depression who have been deterred by the cost of IV ketamine therapy, Spravato® (esketamine) may offer an FDA-approved alternative. Spravato has established insurance coverage pathways for qualifying patients, and treatment is available through certified healthcare settings.
At Seaside Ketamine Newport Beach, Spravato provides another physician-supervised option for patients who meet the appropriate clinical criteria.
Spravato is the brand name for esketamine, a nasal spray containing the S-enantiomer of ketamine. Janssen Pharmaceuticals developed the medication, which received FDA approval in 2019 for adults with treatment-resistant depression (TRD).
The FDA has also approved Spravato for depressive symptoms in adults with major depressive disorder (MDD) who have acute suicidal ideation or behavior. For this indication, patients use Spravato together with an oral antidepressant.
Importantly, the FDA states that Spravato has not been demonstrated to prevent suicide or reduce suicidal ideation or behavior. It also does not replace hospitalization when hospitalization is clinically warranted.
Esketamine is one of two molecular forms, or enantiomers, that make up racemic ketamine. IV ketamine uses the racemic form, while Spravato contains esketamine.
The two treatments also differ in how they are administered. Spravato is delivered as a nasal spray under direct healthcare-provider supervision. Because of potential sedation, dissociation, and respiratory depression, patients must remain under observation for at least two hours after each treatment.
The FDA-approved TRD indication applies to adults with treatment-resistant depression. During an evaluation, the clinician considers the patient’s diagnosis, previous antidepressant treatments, treatment response, and overall medical history.
Patients who have not responded adequately to multiple antidepressant treatments may be candidates for Spravato evaluation. However, meeting general criteria does not guarantee that treatment will be appropriate. Individual medical factors must also be considered.
Spravato is also FDA-approved for depressive symptoms in adults with MDD who have acute suicidal ideation or behavior. For this indication, patients use Spravato together with an oral antidepressant.
This indication does not mean that Spravato itself has been proven to prevent suicide. The FDA specifically states that its effectiveness in preventing suicide or reducing suicidal ideation or behavior has not been demonstrated.
Patients who require hospitalization should still receive appropriate emergency or inpatient care. Spravato should not be viewed as a substitute for emergency treatment when a higher level of care is necessary.
Because Spravato is FDA-approved for specific indications, qualifying patients may have insurance coverage options that are not available for off-label IV ketamine treatment.
Coverage varies by insurance plan and individual circumstances. Prior authorization may be required. Insurance companies may also request documentation of the diagnosis, previous treatment history, and other clinical information.
Spravato’s manufacturer provides patient-support resources that can help eligible patients understand insurance coverage and potential out-of-pocket costs.
At Seaside Ketamine Newport Beach, our team can help patients navigate insurance verification and the authorization process before beginning treatment.
Spravato is administered in a healthcare setting that participates in the Spravato REMS program. Patients self-administer the nasal spray under direct supervision rather than taking the medication independently at home.
After administration, patients remain under observation for at least two hours. Healthcare providers monitor for potential effects such as sedation, dissociation, and respiratory depression.
Before leaving, the healthcare team determines whether the patient is clinically stable enough to go home.
Spravato and IV ketamine both involve ketamine-related medications, but they differ in formulation, administration, regulatory status, dosing, and treatment structure.
Spravato is FDA-approved for specific depression indications. Patients administer it as a nasal spray under clinical supervision. Depending on their insurance plan and clinical circumstances, eligible patients may also have coverage for treatment.
IV ketamine uses racemic ketamine administered intravenously. The FDA has not approved IV ketamine specifically for the treatment of depression, so psychiatric use is considered off-label.
With IV treatment, a physician administers the medication intravenously according to the clinical protocol. Treatment parameters can be individualized based on the patient’s circumstances and response.
Several factors can influence the choice between Spravato and IV ketamine. These include diagnosis, previous treatment response, medical history, insurance coverage, treatment preferences, and clinical goals.
For some patients, Spravato’s FDA-approved indications and potential insurance coverage may make it an option worth discussing. Others may discuss IV ketamine with their physician based on their individual treatment history and clinical circumstances.
Dr. Gillin evaluates each patient’s situation individually. During a consultation, he can discuss whether Spravato, IV ketamine, or another treatment approach may be appropriate.
If you have treatment-resistant depression and conventional treatments have not provided adequate relief, Spravato may be an option to discuss with a qualified physician.
Seaside Ketamine Newport Beach provides physician-supervised ketamine and Spravato treatment for appropriate patients. A consultation with Dr. Gillin can help determine which treatment options fit your diagnosis, treatment history, and individual needs.
Contact your insurance provider directly and ask about Spravato (esketamine) coverage under your plan for treatment-resistant depression. Ask specifically whether prior authorization is required, what clinical documentation is needed, and what your in-network coverage looks like for a certified Spravato treatment site. Seaside Ketamine Newport Beach can also assist with the verification process during your intake consultation — we have experience navigating prior authorization requirements across the major commercial insurers in Orange County.
Yes — this is an FDA requirement, not a clinic preference. Because Spravato can cause dissociation and sedation following administration, all patients must be monitored at the certified treatment site for a minimum of two hours after each dose. You will not be able to drive yourself home after any Spravato session and will need a driver or rideshare. We recommend treating Spravato session days as rest days with no significant obligations scheduled immediately afterward.
Direct head-to-head comparison trials are limited, making a definitive efficacy comparison difficult. Both have demonstrated meaningful antidepressant effects in TRD. IV ketamine has a larger overall research base; Spravato has FDA approval and more rigorous Phase III trial data supporting its specific indications. In practice, both are effective for appropriate candidates. The choice is guided less by a clear efficacy winner and more by clinical picture, insurance coverage, cost, and patient preference — all of which Dr. Gillin discusses directly with you during your consultation.
